Early Prediction of Objective Response of Fibrinogen in a Real-World Cohort of Hepatocellular Carcinoma Cases Treated by Programmed Cell Death Receptor-1 and Lenvatinib

BACKGROUND: This cohort study aimed to investigate the influence of fibrinogen on progression-free survival and overall survival in unresectable HCC cases treated by PD-1 and lenvatinib. METHODS: A total of 57 unresectable HCC cases who received lenvatinib and PD-1, such as toripalimab, camrelizumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Yanjun, Wang, Huige, Wei, Jianying, Li, Wendong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513529/
https://www.ncbi.nlm.nih.gov/pubmed/34675546
http://dx.doi.org/10.2147/OTT.S332351
Descripción
Sumario:BACKGROUND: This cohort study aimed to investigate the influence of fibrinogen on progression-free survival and overall survival in unresectable HCC cases treated by PD-1 and lenvatinib. METHODS: A total of 57 unresectable HCC cases who received lenvatinib and PD-1, such as toripalimab, camrelizumab, or sintilimab, in Beijing Ditan Hospital Affiliated to Capital Medical University were enrolled in this study. RESULTS: Vascular invasion, high FIB (>2.83g/L), and metastasis were highly correlated with low PFS. There was a significant correlation between a raised risk of death and metastasis and increased FIB (>2.83g/L). CONCLUSION: FIB is associated with outcomes of unresectable HCC cases treated by PD-1 and lenvatinib.

Ejemplares similares